Charity: Chagas cardiomyopathy bisoprolol intervention study: A randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]

Trials

Volumn 7, Issue , 2006, Pages

  Quiros, Franklin R ^a   Morillo, Carlos A ^a,b   Casas, Juan P ^c   Cubillos, Luz A ^a   Silva, Federico A ^a  

^a FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

^b MCMASTER UNIVERSITY   (Canada)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; PLACEBO;

ARTICLE; ARTIFICIAL HEART PACEMAKER; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BRADYCARDIA; BRONCHOSPASM; CARDIAC RESYNCHRONIZATION THERAPY; CHAGAS DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COLD LIMB; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEFIBRILLATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FATIGUE; FOLLOW UP; FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPOTENSION; HYPOTHESIS; INFORMED CONSENT; MAINTENANCE DRUG DOSE; MEDICAL ASSESSMENT; METHODOLOGY; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; TASK PERFORMANCE; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; TWO DIMENSIONAL ECHOCARDIOGRAPHY; WALKING;

EID: 33747051806     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-7-21     Document Type: Article

References (26)

1. Araujo RD, Bestetti Rb, Godoy RA, et al.: Chronic Chagas' heart disease in children and adolescents: a clinicopathologic study. In J Cardiol 1985, 9:439-49.
2. Pinto Dias JC: Epidemiology of Chagas' disease in Brazil. In: Brenner RR, Stoka AM, eds. Chagas' disease vectors. CRC press; 1988:57-84.
3. Coura JR: Evolutive patterns in Chagas' disease and the life span of Trypanosome cruzi in human infections. In: New approaches in American trypanosomiasis research. Scientific publication 318. Washington, DC.: Pan American Health Organization; 1976:378-82.
4. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Tenth Programme Report,. Chagas' disease. 1991:69.
5. WHO: Demographic YearBook 1983. New York; 1985.
6. PanAmerican Organization: Status of Chagas' disease in the region of the Americas. Epidemiologic bulletin. Washington, DC: PanAmerican Health Organization; 1984:5-9.
7. Hagar JM, Rahimtoola MB: Current Problems in Cardiology. Chagas' Heart Disease 1995, 12:825-928.
8. Roberti RR, Martinez EE, Andrade JL, et al.: Chagas' Cardiomyopathy and Captopril. Eur Heart J 1992, 13:966-70.
9. Morris SA: Alteration of the pattern of beta-adrenergic desensitization in cultured L6E9 muscle cell infected with Trypanosome cruzi. Mol Biochem Parasitol 1984, 13(2):227-34.
10. Willette RN, Aiyar N, Yue TL, et al.: In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther 1999, 289(1):48-53.
11. Levy P, Lechat P, Leizorovicz A, et al.: A cost minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998, 12(3):301-5.
12. CIBIS II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II: a randomized trial. Lancet 1999, 353:9-13.
13. CIBIS Investigators and Committees: A randomized trial of b-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 1994, 90:1765-73.
14. Kukin ML, Kalman J, Charney RH, et al.: Prospective, randomized comparison of effect of long term treatment with Metoprolol or Carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure. Circulation 1999, 99:2645-51.
15. Australia-New Zealand Heart Failure Research Collaborative Group: Effects of Carvedilol in patients with congestive heart failure due to ischemic heart disease. Circulation 1995, 92:212-8.
16. Packer M, Bristow MR, Cohn JN, et al.: The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-55.
17. Bristol Mr, Giblet EM, Abraham WT, et al.: Carvedilol produces dose related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807-16.
18. Colucci WS, Packer M, Bristow MR, et al.: US Carvedilol Heart Failure Study. Circulation 1996, 94:2800-06.
19. Packer M, Colucci WS, Sackner-Bernstein JD, et al.: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996, 94:2793-99.
20. Haggar J, Rahimtoola S: Chagas' Heart Disease. N Engl J of Med 1991, 325:763-68.
21. Waagstein F, Hjalmarson A, Varnauskas E, et al.: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975, 37:1022-36.
22. Mady C, Antonelli RH, Pereira AC, et al.: Survival and Predictors of survival in patients with congestive heart failure due to Chagas' Cardiomyopathy. Circulation 90:3098-02.
23. Packer M, Coats A, Fowler M, et al.: Effect of Carvedilol on survival in severe chronic heart failure. N Engl J of Med 2001, 344:1651-8.
24. Dargie HJ: Effects of Carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The Carpicorn randomized trial. Lancet 2001, 357:1385-1390.
25. Packer M, Cohn J: Consensus recommendations for the management of chronic heart failure. Am J of Cardiol 1999, 83(2A):1A-38A.
26. Remme W, Swedberg K: Guidelines for the diagnosis ams treatment of chronic heart failure. Eur Heart J 2001, 22:1527-1560.